<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03681132</url>
  </required_header>
  <id_info>
    <org_study_id>2018/988</org_study_id>
    <nct_id>NCT03681132</nct_id>
  </id_info>
  <brief_title>The Norwegian Nucleoside Analogue Stop Study</brief_title>
  <acronym>Nuc-Stop</acronym>
  <official_title>The Norwegian Nucleoside Analogue Stop Study: a Randomized Open-label Trial in HBeAg Negative Chronic Hepatitis B, Aiming at Achieving a Functional Cure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akershus University Hospital, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Addis Ababa University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Paul's Hospital Millennium Medical College, Ethiopia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>South-Eastern Norway Regional Health Authority, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bærum Hospital, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Drammen Hospital, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tønsberg Hospital, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stavanger University Hospital, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ålesund Hospital, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bodø Hospital, Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Globally, an estimated 257 million individuals have chronic hepatitis B-virus infection&#xD;
      (CHB). In the absence of treatment 15-40% of these will progress to liver cirrhosis and/or&#xD;
      hepatocellular carcinoma. Oral antiviral treatment suppresses the virus and improves&#xD;
      prognosis, but less than 0.5% per year achieve a &quot;functional cure&quot; (i.e. HBsAg loss). One&#xD;
      remaining controversy, therefore, is whether antiviral treatment must continue life-long.&#xD;
      Observational studies have assessed stopping antiviral treatment after years of viral&#xD;
      suppression; however, HBsAg loss has rarely been seen. But interestingly, a few small trials&#xD;
      that chose watchful waiting instead of re-initiation of treatment when reactivation occurred,&#xD;
      achieved 40% HBsAg loss during 6 years follow-up.&#xD;
&#xD;
      The present proposal is a randomized controlled trial that will assess the safety, efficacy,&#xD;
      and cost-effectiveness of treatment discontinuation - and delayed restart - in HBeAg negative&#xD;
      CHB. The study is sufficiently powered to address the hypotheses, and a pilot study that&#xD;
      demonstrates feasibility has been performed. Patients will be enrolled at 12 Norwegian&#xD;
      hospitals, in addition to our collaborating institution in Ethiopia - the largest CHB&#xD;
      treatment center in sub-Saharan Africa. If the study shows that discontinuation is safe and&#xD;
      effective, it will directly impact both national and international treatment guidelines.&#xD;
&#xD;
      Main objective:&#xD;
&#xD;
      -To study whether stopping nucleoside analogue (NA) therapy - and delaying re-start - can&#xD;
      trigger an immune response and set off a functional cure (viz HBsAg loss)&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  Assess whether stopping NA therapy - and delaying re-start - leads to a higher chance of&#xD;
           HBsAg loss&#xD;
&#xD;
        -  Assess the safety of stopping NA therapy - and delaying re-start - in terms of hepatic&#xD;
           decompensation, fibrosis progression, and/or adverse events&#xD;
&#xD;
        -  Study whether stopping NA therapy - and delaying re-start - leads to a higher chance of&#xD;
           sustained off-therapy immune control (low viral load and normal ALT)&#xD;
&#xD;
        -  Assess the quality of life and cost-effectiveness of stopping NA therapy - and delaying&#xD;
           re-start&#xD;
&#xD;
        -  Identify predictors of HBsAg loss&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 20, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBsAg loss</measure>
    <time_frame>Within 3 years after stopping therapy</time_frame>
    <description>Undetectable HBsAg measured by a standard assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to HBsAg loss</measure>
    <time_frame>Within 3 years after stopping therapy</time_frame>
    <description>Time from randomization to undetectable HBsAg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to re-start of antiviral therapy</measure>
    <time_frame>Within 3 years after stopping therapy</time_frame>
    <description>Time from randomization to re-start of therapy according to the specified criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe unintended medical events</measure>
    <time_frame>Within 3 years after stopping therapy</time_frame>
    <description>Liver failure or other liver-related grade 4/5 SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune control</measure>
    <time_frame>Within 3 years after stopping therapy</time_frame>
    <description>Sustained off-therapy response viz HBV DNA &lt;2000 IU/ml and ALT &lt;40 U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in health-related quality of life</measure>
    <time_frame>Within 3 years after stopping therapy</time_frame>
    <description>Changes in the EuroQol standardized measure of health status (EQ-5D-5L) score. The summary index (from 0 to 1) as described by the manufacturer (euroqol.org) will be employed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver fibrosis evolution</measure>
    <time_frame>Within 3 years after stopping therapy</time_frame>
    <description>Changes in transient elastography from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Low-threshold re-start</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Re-start antiviral therapy if HBV DNA viral load &gt;2000 IU/ml and ALT &gt;80 U/L.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-threshold re-start</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Re-start antiviral therapy if:&#xD;
ALT &gt;100 U/L persisting for more than 4 months without any spontaneous decline toward normal; OR&#xD;
ALT &gt;400 U/L persisting for more than 2 months in consecutive assays.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stop of therapy</intervention_name>
    <description>The active intervention is to stop antiviral therapy, and delay re-start in the high-threshold group.</description>
    <arm_group_label>High-threshold re-start</arm_group_label>
    <arm_group_label>Low-threshold re-start</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (18-70 years) with HBeAg negative chronic hepatitis B&#xD;
&#xD;
          -  HBeAg negative at start of antiviral therapy&#xD;
&#xD;
          -  Treated minimum 2 years with either tenofovir or entecavir without interruption (i.e.&#xD;
             no self-reported episodes of ≥2 weeks off therapy)&#xD;
&#xD;
          -  Full viral suppression &gt;2 years: at least 3 measurements at least 6 months apart with&#xD;
             at least 24 months between the first and last measurement.&#xD;
&#xD;
          -  Most recent liver fibrosis assessment, performed within the past 12 months, does not&#xD;
             show advanced fibrosis (i.e. Metavir score &lt;F3 or Fibroscan &lt;9 kPa). For the (few)&#xD;
             patients who lack pre-treatment fibrosis assessment, a more conservative Fibroscan&#xD;
             threshold of &lt;8 kPa will apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of decompensated liver disease, either by clinical signs (ascites,&#xD;
             encephalopathy, portal hypertension, jaundice) or suggestive laboratory results (total&#xD;
             bilirubin &gt;38 umol/L, INR &gt;1.5, platelets &lt;75,000/mm3, serum albumin &lt;30 g/L).&#xD;
&#xD;
          -  Any previous diagnosis of cirrhosis, either by liver biopsy (Metavir score F4) or&#xD;
             elastography (Fibroscan &gt;12 kPa). Elastography results with concomitant ALT &gt;200 U/L&#xD;
             are not considered.&#xD;
&#xD;
          -  Previous hepatocellular carcinoma (HCC).&#xD;
&#xD;
          -  Co-infections with HIV, hepatitis C or hepatitis D.&#xD;
&#xD;
          -  Other disease or medication that can interfere with the study (e.g. ongoing alcohol or&#xD;
             illicit drug abuse, immunosuppressive medication, other active liver disease, or any&#xD;
             other condition which in the opinion of the physician is incompatible with&#xD;
             participation)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>København</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Paul Hospital Millennium Medical College</name>
      <address>
        <city>Addis Abeba</city>
        <country>Ethiopia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bodø Hospital</name>
      <address>
        <city>Bodø</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drammen Hospital</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bærum Hospital</name>
      <address>
        <city>Sandvika</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tønsberg Hospital</name>
      <address>
        <city>Tønsberg</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ålesund Hospital</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karonlinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Ethiopia</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Asgeir Johannessen</investigator_full_name>
    <investigator_title>Consultant/ researcher</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

